AB
Allison Bratzel Piper Sandler Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
argenx
ARGX
$45.9B
| $750.78 | $820 |
9%
upside
| Overweight | 10 days ago |
|
2
Ionis Pharmaceuticals
IONS
$9.76B
| $61.23 | $65 |
6%
upside
| Overweight | 14 days ago |
|
|
ABVX
3
Abivax
ABVX
$6.47B
| $88.03 | $112 |
27%
upside
| Overweight | 1 month ago |
|
4
Replimune Group
REPL
$494M
| $6.33 | $22 |
248%
upside
| Overweight | 3 months ago |
|
5
Tyra Biosciences
TYRA
$674M
| $12.65 | $33 |
161%
upside
| Overweight | 3 months ago |
|
6
Ultragenyx Pharmaceutical
RARE
$3.07B
| $31.82 | $115 |
261%
upside
| Overweight | 5 months ago |
|
7
Akebia Therapeutics
AKBA
$785M
| $2.96 | $6 |
103%
upside
| Overweight | 5 months ago |
|
8
enGene Holdings
ENGN
$265M
| $5.18 | $26 |
402%
upside
| Overweight | 6 months ago |
|
9
Travere Therapeutics
TVTX
$1.93B
| $21.64 | $22 |
2%
upside
| Neutral | 9 months ago |
|
10
Rigel Pharmaceuticals
RIGL
$742M
| $41.34 | $23 |
44%
downside
| Neutral | 9 months ago |
|
11
Scholar Rock
SRRK
$3.02B
| $31.41 | $42 |
34%
upside
| Overweight | 10 months ago |
|
12
Roivant Sciences
ROIV
$8.82B
| $12.92 | $22 |
70%
upside
| Overweight | 1 year ago |
|
13
Solid Biosciences
SLDB
$428M
| $5.50 | $20 |
264%
upside
| Overweight | 1 year ago |
|
14
AbCellera Biologics
ABCL
$1.26B
| $4.22 | $20 |
374%
upside
| Overweight | 1 year ago |
|
15
Incyte
INCY
$16.9B
| $86.64 | $100 |
15%
upside
| Overweight | 2 years ago |
|